Need to Know: Social media can be a powerful tool to directly advertise ongoing clinical trials to target patients, but such an unregulated space increases the risk of companies being exposed of negative or untrue comments. While having an inhouse press team allows a pharma company to have a dedicated crew for its communication plans, […]

Athira Pharma has dosed the first subject in the Phase I clinical trial of its treatment candidate, ATH-1020, to potentially treat neuropsychiatric conditions. An orally available, brain-penetrant small molecule, ATH-1020 is created to boost HGF/MET system. The first-in-human placebo-controlled, randomised, double-blind, two-part trial will assess the safety, tolerability and pharmacokinetics of single and multiple ascending doses of […]

NeuroSense Therapeutics plans to enroll 70 patients with fast-progressing amyotrophic lateral sclerosis (ALS) in its planned Phase IIb trial of PrimeC, CEO Alon Ben-Noon says. The trial will randomise patients 2:1 between PrimeC and placebo during a blinded six-month treatment period, followed by a six-month, open-label treatment period, he adds. PrimeC is an extended-release version […]